Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Re­gen­eron can’t dodge a law­suit al­leg­ing it un­law­ful­ly in­flat­ed Medicare re­im­burse­ments for its eye drug Eylea and de­fraud­ed the US out of hun­dreds of mil­lions … ...

Consequently, low-cost off-label repackaged Avastin increased its anti-VEGF category share by approximately 6 percentage points to 32%. Despite these challenges, EYLEA HD and EYLEA captured 41% of ...

Eylea, or aflibercept, had global sales of just under $10 billion in 2024, thanks to its strong competitive positioning and more attractive dosing regimen versus Lucentis and Avastin in ...

Regeneron reported quarterly revenue contraction of 4% year on year, which was largely driven by declines in its Eylea franchise. Original dose Eylea declined 39% year on year and 38% sequentially ...

The supplemental application is for the addition of extended dosing intervals (up to every 24 weeks) of EYLEA HD injection 8 mg across all approved indications. The FDA disagreed with Regeneron ...

Total revenues decreased 4% year over year to $3 billion due to lower sales of lead drug Eylea. Revenues also missed the Zacks Consensus Estimate of $3.27 billion. Sales of oncology drug ...

Thank you for signing up! Did you know with a Digital Subscription to Yorkshire Evening Post, you can get unlimited access to the website including our premium content, as well as benefiting from ...

In the first quarter, U.S. net sales for Eylea HD and Eylea decreased 26% year-over-year to $1.04 billion, including $307 million from Eylea HD. Also Read: FDA Sets The Countdown: Regeneron’s ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...